Radiant Launches Bangladesh's 1st Covid-19 Antibody Medicine

The global epidemic of coronavirus infection is on the rise again. At the same time, the number of patients with covid-19 in Bangladesh is increasing at an alarming rate. In this context, Radiant Pharmaceuticals has introduced the first monoclonal antibodies in Bangladesh for the effective treatment of high-risk covid-9 patients. Antibodies are able to reduce hospital admissions of covid-19 patients by about 70 percent.